Next-generation sequencing (NGS) detected mutations in DNMT3A and UBA1, leading to a diagnosis of low-risk MDS (IPSS-R of 2) and VEXAS syndrome. The gene discussed is DNMT3A; the disease is VEXAS syndrome.